Oramed Pharmaceuticals (NASDAQ:ORMP) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.09), Fidelity Earnings reports. Oramed Pharmaceuticals had a negative return on equity of 28.75% and a negative net margin of 230.07%.
Shares of Oramed Pharmaceuticals stock traded up $0.02 during trading on Friday, reaching $4.48. 6,912 shares of the company traded hands, compared to its average volume of 164,833. Oramed Pharmaceuticals has a 1-year low of $2.40 and a 1-year high of $5.71. The company has a 50 day moving average price of $4.28 and a 200-day moving average price of $3.45. The firm has a market capitalization of $106.07 million, a PE ratio of -13.51 and a beta of 1.58.
Separately, Alliance Global Partners initiated coverage on shares of Oramed Pharmaceuticals in a research report on Thursday, December 3rd. They issued a “buy” rating and a $11.00 price target on the stock.
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes.
Further Reading: Limitations of analyzing profit margin
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.